U.S. Markets closed

Vical Incorporated (VICL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.39-0.02 (-0.83%)
At close: 4:00PM EDT

2.43 +0.04 (1.67%)
After hours: 5:29PM EDT

People also watch
BCRXHEBLGNDXOMAPGNX

Vical Incorporated

10390 Pacific Center Court
San Diego, CA 92121
United States
858-646-1100
http://www.vical.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees73

Key Executives

NameTitlePayExercisedAge
Mr. Vijay B. SamantChief Exec. Officer, Pres and Director905.94kN/A64
Mr. Anthony Alan RamosChief Financial Officer & Principal Accounting Officer336.63kN/A50
Dr. Lawrence Russell Smith Ph.D.Sr. VP of Research360.95kN/A56
Mr. Keith D. Hall M.D.VP of OperationsN/AN/A55
Dr. Mammen P. Mammen Jr., M.D.Sr. VP of Clinical Devel.N/AN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy. The company also engages in contract manufacturing of plasmid investigational products for various clients. It has collaborations with Astellas to develop and commercialize certain products, including ASP0113 for the control and prevention of CMV infection in immunocompromised patients; and Merial for use of the company’s core DNA delivery technology in a therapeutic vaccine designed to aid in extending survival time of dogs with oral melanoma. It also has a license agreement with Astellas to develop and commercialize novel antifungal candidate. The company was founded in 1987 and is headquartered in San Diego, California.

Corporate Governance

Vical Incorporated’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.